HSBC Holdings’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

HSBC Holdings’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,257	Closed	-$25.5K	–	2846
2023 Q1	$25.5K	Hold	17,257	–	–	﹤0.01%	2595
2022 Q4	$16.9K	Sell	17,257 -1,544	-8%	-$2.08K	﹤0.01%	3022
2022 Q3	$33K	Sell	18,801 -293	-2%	-$850	﹤0.01%	2851
2022 Q2	$56K	Hold	19,094	–	–	﹤0.01%	3125
2022 Q1	$53K	Hold	19,094	–	–	﹤0.01%	3196
2021 Q4	$92K	Buy	+19,094	New	+$119K	﹤0.01%	3157

HSBC Holdings's TCRR Position: Q2 2023 in Review

HSBC Holdings sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 17,257 shares — an estimated $25.5K sold.

HSBC Holdings first reported a position in TCRR in Q4 2021 and held it in 6 quarters. The position peaked at $92K in Q4 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

HSBC Holdings reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
HSBC Holdings sold 17,257 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $25.5K.
HSBC Holdings first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2021 and held it in 6 quarters.
HSBC Holdings's TCR2 Therapeutics Inc. Common Stock position peaked at $92K in Q4 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on HSBC Holdings's 13F filing for Q2 2023, filed 11 Aug 2023.